Oncopeptides AB (publ) (STO:ONCO)
Sweden
· Delayed Price · Currency is SEK 1.596
+0.020 (1.27%)
Mar 10, 2026, 11:39 AM CET
Oncopeptides AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 71.12 | 31.65 | 35.22 | 8.36 | 118.3 | Upgrade
|
| Revenue Growth (YoY) | 124.72% | -10.14% | 321.54% | -92.94% | - | Upgrade
|
| Cost of Revenue | 2.45 | 2.66 | -1.08 | 0.01 | 53.12 | Upgrade
|
| Gross Profit | 68.67 | 28.99 | 36.3 | 8.35 | 65.17 | Upgrade
|
| Selling, General & Admin | 194.62 | 197.28 | 188.48 | 142.2 | 873.81 | Upgrade
|
| Research & Development | 102.97 | 121.19 | 106.95 | 217.66 | 679.93 | Upgrade
|
| Other Operating Expenses | -4.27 | -6.9 | -6.34 | -4.57 | 3.9 | Upgrade
|
| Operating Expenses | 293.32 | 311.57 | 289.09 | 355.29 | 1,558 | Upgrade
|
| Operating Income | -224.65 | -282.59 | -252.79 | -346.94 | -1,492 | Upgrade
|
| Interest Expense | -23.52 | -12.66 | -5.79 | -0.88 | -0.95 | Upgrade
|
| Interest & Investment Income | - | 8.2 | 8.59 | 2.62 | 0.49 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 2.84 | 1.54 | 8.96 | 71.54 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 0 | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -248.17 | -284.21 | -248.45 | -336.24 | -1,421 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -1.44 | - | Upgrade
|
| Pretax Income | -248.17 | -284.21 | -248.45 | -337.68 | -1,421 | Upgrade
|
| Income Tax Expense | 1.42 | 0.4 | 0.66 | 0.27 | 8.95 | Upgrade
|
| Net Income | -249.59 | -284.61 | -249.11 | -337.95 | -1,430 | Upgrade
|
| Net Income to Common | -249.59 | -284.61 | -249.11 | -337.95 | -1,430 | Upgrade
|
| Shares Outstanding (Basic) | 227 | 166 | 90 | 82 | 75 | Upgrade
|
| Shares Outstanding (Diluted) | 227 | 166 | 90 | 82 | 75 | Upgrade
|
| Shares Change (YoY) | 36.32% | 84.14% | 9.80% | 9.33% | 20.72% | Upgrade
|
| EPS (Basic) | -1.10 | -1.71 | -2.76 | -4.11 | -19.00 | Upgrade
|
| EPS (Diluted) | -1.10 | -1.71 | -2.76 | -4.11 | -19.00 | Upgrade
|
| Free Cash Flow | -216.49 | -260.93 | -279.61 | -423.02 | -1,517 | Upgrade
|
| Free Cash Flow Per Share | -0.95 | -1.57 | -3.09 | -5.14 | -20.14 | Upgrade
|
| Gross Margin | 96.55% | 91.59% | 103.06% | 99.93% | 55.09% | Upgrade
|
| Operating Margin | -315.88% | -892.91% | -717.74% | -4152.44% | -1261.64% | Upgrade
|
| Profit Margin | -350.94% | -899.29% | -707.30% | -4044.90% | -1209.11% | Upgrade
|
| Free Cash Flow Margin | -304.41% | -824.47% | -793.89% | -5063.03% | -1282.16% | Upgrade
|
| EBITDA | -222.18 | -280.12 | -250.35 | -344.93 | -1,491 | Upgrade
|
| D&A For EBITDA | 2.47 | 2.47 | 2.44 | 2.01 | 1.72 | Upgrade
|
| EBIT | -224.65 | -282.59 | -252.79 | -346.94 | -1,492 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.